Vanda Pharmaceuticals - VNDA Stock Forecast, Price & News

Vanda Pharmaceuticals' stock was trading at $7.39 at the start of the year. Since then, VNDA stock has decreased by 8.8% and is now trading at $6.74.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our VNDA earnings forecast.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.20 by $0.06. The biopharmaceutical company had revenue of $70.10 million for the quarter, compared to the consensus estimate of $73.50 million. Vanda Pharmaceuticals had a net margin of 2.47% and a trailing twelve-month return on equity of 1.22%. During the same period last year, the business earned $0.11 earnings per share.

ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), iShares Neuroscience and Healthcare ETF (IBRN), Roundhill Acquirers Deep Value ETF (DEEP), Invesco S&P SmallCap Health Care ETF (PSCH), First Trust Active Factor Small Cap ETF (AFSM), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO) and iShares U.S. Pharmaceuticals ETF (IHE).

12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Vanda Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.11%), Dimensional Fund Advisors LP (5.04%), Millennium Management LLC (3.15%), Assenagon Asset Management S.A. (2.81%), Epoch Investment Partners Inc. (2.47%) and Macquarie Group Ltd. (2.33%). Insiders that own company stock include Aranthan Jones II, Gunther Birznieks, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell, Thomas Watkins and Timothy Williams.
View institutional ownership trends.

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VNDA stock can currently be purchased for approximately $6.74.

Vanda Pharmaceuticals (NASDAQ:VNDA) has a market capitalization of $382.73 million and generates $254.38 million in revenue each year. The biopharmaceutical company earns $6.28 million in net income (profit) each year or $0.12 on an earnings per share basis.

The company employs 278 workers across the globe.

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The official website for the company is www.vandapharma.com. The biopharmaceutical company can be reached via phone at (202) 734-3400, via email at pr@vandapharma.com, or via fax at 202-296-1450.